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Atherosclerosis is commonly appreciated to represent a chronic inflammatory response of the vascular wall, and its
complications cause high mortality in patients. Angioplasty with stent replacement is commonly performed in
patients with atherosclerotic disease. However, the restenosis usually has a high incidence rate in angioplasty
patients. Although the pathophysiological mechanisms underlying atherosclerosis and restenosis have been well
established, new signaling molecules that control the progress of these pathologies have continuously been
discovered. MicroRNAs (miRs) have recently emerged as a novel class of gene regulators that work via
transcriptional degradation and translational inhibition or activation. Over 30% of genes in the cell can be directly
regulated by miRs. Thus, miRs are recognized as crucial regulators in normal development, physiology and
pathogenesis. AIterations of miR expression profiles have been revealed in diverse vascular diseases. A variety of
functions of vascular cells, such as cell differentiation, contraction, migration, proliferation and inflammation that are
involved in angiogenesis, neointimal formation and lipid metabolism underlying various vascular diseases, have
been found to be regulated by miRs. This review summarizes current research progress and knowledge on the
roles of miRs in regulating vascular cell function in atherosclerosis and restenosis. These discoveries are expected to
present opportunities for clinical diagnostic and therapeutic approaches in vascular diseases resulting from
atherosclerosis and restenosis.Review
Introduction
Atherosclerosis is a chronic and progressive pathology
characterized by the accumulation of lipid and fibrous
elements in the large arteries, which causes a number of
cardiovascular-related diseases. Atherosclerosis has a tre-
mendous impact in developing and developed countries,
representing the underlying cause of approximately 50%
of deaths. Our knowledge of the pathophysiology for this
important malady has evolved over the past century. Ex-
tensive evidence reveals that the pathogenic feature of ath-
erosclerosis is an inflammatory process, in which vascular
endothelial cells (ECs) become dysfunctional due to influ-
ences by chemical substances, such as cytokines and
growth factors [1], and hemodynamic forces [2]. Activated
ECs with high expression levels of various leukocyte adhe-
sion molecules recruit leukocytes and monocytes to bind
to the endothelium and migrate into the vessel wall. The* Correspondence: jjchiu@nhri.org.tw
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reproduction in any medium, provided the orlesion then experiences the following steps: foam cell for-
mation, fatty streak accumulation, migration and prolifera-
tion of vascular smooth muscle cells (VSMCs), and fibrous
cap formation. Finally, the rupture of the unstable fibrous
cap causes thrombosis in complications of advanced
lesions that lead to unstable coronary syndromes, myocar-
dial infarction and stroke. The knowledge that atheroscler-
osis is a vascular pathology resulting from inflammatory
response enables new approaches to treatment and preven-
tion. Immunosuppressant and anti-inflammatory agents
could potentially be applied in clinical trials. However, sur-
gical treatments remain the prevalent method of treating
in the patients with atherosclerosis, including percutaneous
transluminal coronary angioplasty (PTCA) and stent
placement.
Angioplasty and stent placement remove the occlusion to
augment the inner diameter of the artery at various vascular
locations. These treatments exclusively improve the
hemodynamic flow rate and lead to normal blood flow.
While these treatments have been used in many patients
with atherosclerotic disease over the past decades, restenosis
is an ongoing complication with an incidence of 30–40%td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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atherosclerosis are recognized as inflammatory processes in
response to injury [3], restenosis is in fact a vascular injury
caused by balloon dilation and stent replacement during
angioplasty [4]. The development of restenosis is patho-
physiologically distinct from atherosclerosis. These differ-
ences have been observed during the proliferation and
migration of VSMCs, extracellular matrix remodeling and
neointimal hyperplasia. Anatomic and procedural clinical
variables are associated with an increased incidence of re-
stenosis following angioplasty [5].
MicroRNAs (miRs) are recently emerging endogenous,
noncoding, single-stranded RNAs of 18–22 nucleotides
that constitute a novel class of gene regulators. The first
miR, lin-4, was discovered during the development of
Caenorhabditis elegans in 1993 [6]. Bentwich et al. [7]
developed an integrative approach combining bioinformatic
prediction with microarray analysis and sequence-directed
cloning to reveal that more than 800 miRs exist in humans.
Currently, over 15,000 miR gene loci have been identified
in over 140 species, and more than 17,000 distinct mature
miR sequences are present in the miRBase16 [8]. MiRs bind
to their target genes in 3’-untranslated regions (3’-UTRs),
leading to the direct degradation of messenger RNA
(mRNA) or translational repression by a perfect or imper-
fect complement. This implies that miRs are able to regu-
late the expression of hundreds or thousands genes. Thus,
it is not surprising that miRs are involved in the regulation
of all major cellular functions [9].
The pathophysiological mechanisms of vascular path-
ologies such as atherosclerosis, hypertension, coronary
artery disease and restenosis after angioplasty have been
well established over the past decades. Vascular proper-
ties including angiogenesis, re-endothelialization and
neointima formation contribute to these vascular path-
ologies/diseases. Inflammatory responses to injury, dif-
ferentiation, proliferation, migration and apoptosis of
VSMCs or ECs are critical cellular events for the devel-
opment of these vascular diseases. Blood cell recruit-
ment, infiltration, activation and differentiation are also
involved in these complicated diseases. Vascular diseases
have been widely explored, and many new molecules
have been studied as potential clinical therapies. In re-
cent years, the roles of miRs have gradually received in-
creasing attention in the biology of vascular diseases.
Altered miR expression profiles have been related to car-
diovascular diseases in over 400 studies. Although sev-
eral review articles have described the regulation of
miRs in vascular remodeling, inflammation and diseases
[10-12], the specific role of miRs in the regulation of
atherosclerosis and restenosis is barely described. Hence,
this review focuses on the roles of miRs in different
types of vascular cells in relation to atherosclerosis and
restenosis.The biogenesis of microRNA
Primary miR
Most miR genes are located in intronic regions, which
may be transcribed as part of the mRNA genes. As for
general mRNA, miR genes are commonly transcribed by
RNA polymerase II (pol II) [13] in the nucleus (Figure 1).
The primary miR transcripts (pri-miRs) contain capped
structures and polyadenylated (poly A) tails, the hallmark
properties of class II gene transcripts [14]. Besides pol II,
Borchert et al. [15] found that C19MC miRs, including
miR-515-1, miR-517a, miR-517c and miR-519a-1, are
expressed by RNA polymerase III (pol III). Some miRs
contain primary transcripts to produce a single miR,
whereas other transcripts encode proteins in their exons
and miRs. The cluster miRs such as the miR-17~92 family
are grouped together in one cluster on a single unpro-
cessed transcript and expressed together.
Precursor miR
Following transcription by pol II or pol III, the pri-miR
received is endonucleolytically cleaved to an ~60–100 nu-
cleotide hairpin structure with an ~2 nucleotide 3’ over-
hang termed the precursor-miR (pre-miR) by the nuclear
microprocessor complex. This microprocessor complex is
formed by the RNase III enzyme Drosha (RNASEN) and
its partner DGCR8 (DiGeorge critical region 8), also
known as Pasha (Partner of Drosha) in D. melanogaster
and C. elegans [16-18]. Several molecules were identified to
be involved in the post-transcriptional modulation of miR
processing [19]. For example, RNA helicases p68 and p72,
the cofactors of the microprocessor complex, promote the
Drosha cleavage of a subset of miRs. p53, an important
tumor suppressor protein, is present in the complex with
p68 and Drosha to enhance the Drosha processing of a
subset of miRs. Smad, transforming growth factor (TGF)-β
and bone morphogenetic protein (BMP)-specific signaling
transducer proteins are recruited to a consensus sequence
(R-SBE) within the stem region of the primary transcripts
of TGF-β/BMP-miRs in the Drosha and p68 complex.
Thus, this Smad-Drosha-p68 complex promotes the pro-
cessing of TGF-β/BMP-miRs [20]. After nuclear proces-
sing, the pre-miR is exported into the cytoplasm by
Exportin-5 (XPO5) in complex with Ran-GTP cofactor
[21].
Mature miR
The pre-miR is further processed in the cytoplasm by an-
other RNase III Dicer, which forms the RISC complex
with Argonaute 2 (Ago2) and TRBP (Tar RNA binding
protein), which cleaves off the hairpin loop of the pre-miR
to generate an ~22-nucleotide miR duplex [22-24]. This
miR duplex contains mature miR referred to as the guide
strand and a complementary strand referred to as the pas-



























Figure 1 The canonical pathway of miR processing. The primary miR (pri-miR) are transcripted by either RNA polymerase II or III from
independent gene in the nucleus. In the following processing, the microprocessor complex (Drosha-DGCR8) processes pri-miR into a ~60-100-
nucleotide precursor hairpin (pre-miR). The resulting pre-miR is exported to the cytoplasm by Exportin-5-Ran-GTP. In the cytoplasm, the RNase III
Dicer and TRBP cleave the pre-miR into ~22-nucleotide miR/miR* duplex. One strand termed as guide strand, further representing a mature miR,
the miR* termed as passenger strand, which undergoes degradation rapidly. Mature miR is incorporated into a miRISC and base-paired to its
target mRNAs for mRNA degradation or translational repression.
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entially incorporated into a miR-induced silencing com-
plex (miRISC) that contains Dicer and other associated
proteins [25], whereas the miR* is released and rapidly
degraded. As part of the miRISC, the miR is base-paired
to its target mRNA to induce translational repression or
direct degradation [26,27].
Atherosclerosis
A growing body of studies reveals that the pathogenic fea-
ture of atherosclerosis is an inflammatory process involving
ECs in response to injury. These dysfunctional ECs lead to
a sequence of inflammatory responses, blood-cell accumu-
lation, foam cell formation, fibrous formation, advanced
plaque formation and rupture [1,28,29]. These complicated
processes are contributed by various blood cells such as
monocytes, macrophages, and lymphocytes, and vascularcells such as ECs and VSMCs. Moreover, these cells influ-
ence each other and secrete various cytokines and growth
factors to promote the formation of atherosclerosis.
Initiation step
The endothelium consists of a single layer of vascular ECs
and serves as a selective barrier between blood and tissues.
Atherosclerotic plaques preferentially occur in specific ar-
terial sites such as branches, bifurcations and curvatures in
which the flow pattern is disturbed, with a lower velocity
and no particular orientation. ECs tend to turn over in
these regions and show increased permeability to macro-
molecules such as low-density lipoprotein (LDL). As a re-
sult, LDL diffuses passively through EC junctions and
accumulates in the subendothelial matrix. Subsequently,
the LDL undergoes modification and oxidation, contribut-
ing to inflammation and further foam cell formation.
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In the initial lesion, ECs have an activated and pro-
inflammatory phenotype that leads to expression of vari-
ous EC adhesion molecules (such as intercellular adhesion
molecule-1 [ICAM-1], vascular cell adhesion molecule-1
[VCAM-1] and E-selectin), growth factors such as macro-
phage colony stimulating factor (M-CSF), and chemokines
including monocyte chemotactic factor-1 (MCP-1) [30].
E-selectin is a member of the selectin family of adhesion
molecules that plays a crucial role in the initial interaction
between circulating leukocytes and ECs. E-selectin binds
to carbohydrate ligands on the leukocytes and facilitates
the rolling of leukocytes along the endothelial surface.
Under the cooperation of adhesion molecules and chemo-
tactic factors, the rolling leukocytes enter the vessel wall.
In addition, the circulating monocytes and lymphocytes
are recruited by MCP-1 and M-CSF into the vessel wall.
M-CSF promotes macrophage proliferation and differenti-
ation and the expression of scavenger receptors (SR),
which increases the production of cytokines and growth
factors by these cells. LDL has to be modified and oxidized
before it can be taken up by macrophages. The reactive
oxygen species (ROS) produced by vascular cells, includ-
ing sphingomyelinase, secretory phospholipase-2 (sPLA2)
and myeloperoxidase, are involved in the initiation of oxi-
dation of the LDL (oxLDL) [31]. The oxLDL particles are
recognized by macrophage scavenger receptors such as
scavenger receptor-A (SR-A), CD36 antigen (CD36) and
macrophage antigen CD68. Consequently, the oxLDL is
rapidly taken up by macrophages that then become
enlarged and full of lipids. These cells accumulate in the
subendothelial matrix and transform into foam cells, char-
acteristic of the early atherosclerotic lesion (atheroma).
Fibrous plaques
Arteries generally consist of three layers, the intima, media
and adventitia. The normal media layer contains mostly
contractile VSMCs and a few fibroblasts surrounded by
their own basement membrane. The major components of
the medial extracellular matrix are fibrillar collagen type I
and III. In atherosclerosis, the inflammatory response trig-
gers the activated macrophages and T-cells to secrete a
number of cytokines and growth factors that promote the
change of VSMCs from the quiescent contractile state
(differentiation) to the active synthetic state (de-differenti-
ation) [32], the migration from the media to the intima
and the production of collagen (fragments of collagen type
I, III, and collagen type VIII [33]), elastin and proteoglycan
to form a fibrous matrix.
Advanced lesions and plaque disruption
The fibrous cap gradually covers the lipids, leading to the
death of foam cells and other cell debris that form a nec-
rotic core. The inflammatory response and continuousrecruitment of leukocytes and macrophages lead to these
lesions and the expansion of their area. The necrotic core
represents the secretion of various growth factors (e.g.,
platelet-derived growth factor [PDGF] and TGF-β), cyto-
kines (e.g., interleukin [IL]-1 and tissue necrotic factor-α
[TNF-α]), osteopontin and matrix metalloproteinases
(MMPs). Activated T-cells stimulate the production of
MMPs, which promote the instability of the lesion and fur-
ther complicate the inflammatory response. Thinning of
the fibrous cap may result from MMPs such as collage-
nases, elastases, and stromelysins. These MMPs cause the
degradation of the matrix, which could lead to hemorrhage
from the vasa vasorum or from the lumen of the artery
and cause thrombus formation and arterial occlusion.
Restenosis
Restenosis occurs in patients with atherosclerotic disease
undergoing coronary angioplasty with stent replacement.
Even with the best medical techniques, restenosis occurs in
approximately 30% of patients [34]. Although restenosis
and atherosclerosis are recognized as inflammatory pro-
cesses in response to injury, restenosis has a different
pathophysiological appearance than atherosclerosis and
has already been considered a developmentally different
process [4]. The swelling of diseased vessels by either
angioplasty or stent insertion causes endothelial disruption,
fragment of the internal elastic lamina, and dissection of
the media, often extending into the adventitia. Thus, re-
stenosis after angioplasty or stent insertion is a combin-
ation of biological processes, each of which contributes to
the final luminal narrowing. Processes observed in animal
models and patients include elastic recoil, thrombus,
neointima formation and remodeling [35].
Elastic recoil
The human coronary artery is highly elastic, with elastin
fibers comprising the internal elastin lamina (IEL) and ex-
ternal elastin lamina (EEL). In an eccentric atherosclerotic
lesion, the balloon dilatation overstretches the segments of
the artery. The elastic recoil occurs within seconds to min-
utes following balloon dilatation. Over the next days to
weeks, the stretched segments become gradually relaxed,
leading to a reduction of the luminal diameter. Vasocon-
strictors such as serotonin and thromboxane are released
by the aggregating platelets that promote vasoconstriction
at the site of angioplasty [5].
Thrombus
Successful angioplasty usually causes endothelial denuda-
tion and induces medial dissection. The consequent ex-
posure of subintimal components, such as collagen, von
Willebrand factor, fibronectin, and laminin, causes platelet
adherence and aggregation. Many platelets can then be-
come cross-linked by fibrinogen, promoting more platelet
Table 1 Selected miRs involved in the regulation of
vascular endothelial cell function
Function miRs Targets Reference




miR-155 AT1R, Ets-1 [40]
Angiogenesis miR-17~92 cluster ITGA5 [43]
miR-100 mTOR [44]
miR-126 Spred-1, PIK3R2 [39,45-47]
miR-132 p120RasGAP [48]
miR-210 Efn3a [49]
miR-221 Cdkn16, PIK3R1 [50]
miR-222 STST5A [51]
miR-424 MEK1, cyclin E1 [52]
miR-503 Cdc25A, CCNE1 [53]




miR-218 Robo1/2, GLCE [57]
miR-320 IGF-1 [58]
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thromboxane A2 and serotonin, which also promotes fur-
ther adhesion and aggregation. Platelets also secrete a
number of mitogens and chemotactic factors for VSMCs,
including PDGF and TGF-β, which lead to neointima for-
mation at the site of angioplasty [5].
Neointima formation
Neointima formation, known as intimal hyperplasia, is
caused by the proliferation and migration of VSMCs and
the accumulation of fibroblasts at the site of injury. Based
on the observation of specimens from patients, the migra-
tion and proliferation of VSMCs and fibroblasts in the
neointimal layer occurs in the weeks to months after angio-
plasty. Angioplasty induces EC denudation and mechanical
stretching of vessels, which lead to the release of various
cytokines and growth factors by ECs, inflammatory cells
and platelets promoting VSMC proliferation and migration
and increasing the synthesis of the collagen, elastin and
proteoglycan matrix [36].
Remodeling
Remodeling is described as a gradual process of relative
changes in vessel size. Remodeling can be classified into
positive remodeling (also termed outward/expansive re-
modeling) and negative remodeling (termed inward/con-
strictive remodeling). Restenosis may be caused by the
negative remodeling of a dilated artery with less neointima
formation. In contrast, the positive remodeling of a dilated
artery may accumulate large amounts of neointimal tissue.
Mintz et al. [34] further documented negative remodeling
in a series of 209 angioplasty patients and observed that a
significant portion of lumen loss was due to vessel con-
striction rather than neointimal thickening. However, the
mechanisms by which negative remodeling can be involved
in restenosis remain unclear. The extracellular matrix may
be involved in the remodeling of dilated arteries after
angioplasty. Angioplasty causes an acute alteration of
extracellular matrix synthesis and degradation, resulting in
an increase of collagen synthesis and a reduction of MMP
activity, reducing matrix degradation.
Roles of microRNA in vascular cells
Endothelial cells
Inflammation
The pathogenic feature of atherosclerosis is an inflammatory
process by which blood vessels respond to injury. Recent
studies have reported that miRs are involved in these pro-
cesses (Table 1). Vessels from swine exhibited decreased ex-
pression of miR-10a at athero-susceptible regions of the
inner aortic arch and aorta-renal branches. To further dem-
onstrate the role of miR-10a knockdown, the effects of miR-
10a knockdown on the endothelial transcriptome weredetermined in cultured ECs by whole-genome microarray
analyses. Bioinformatic analysis identified IκB/NF-κB–
mediated inflammation as the main biological processes tak-
ing place in miR-10a knockdown cells. Downregulation of
miR-10a enhances IκB/NF-κB activation and leads to signifi-
cant upregulation of inflammatory biomarkers such as
MCP-1, VCAM-1, E-selectin, IL-6 and IL-8. This evidence
suggests that miR-10a suppresses pro-inflammatory mole-
cules in endothelial phenotypes of the athero-susceptible re-
gion in vivo [37]. Through in silico analysis, Harris et al.
[38] and Wang et al. [39] suggested that miR-126 may be a
negative regulator of VCAM-1 expression. Overexpression
of miR-126 by oligonucleotide transfection led to repression
in TNF-α-induced protein expression of VCAM-1 and
leukocyte adhesion. Moreover, miR-126 was identified to be
involved in the regulation of VCAM-1 at the translational
rather than transcriptional level. This result enhances the
importance of miR-126 in posttranscriptional gene regula-
tion in ECs. MiR-155 was demonstrated to play an anti-
inflammatory role in ECs [40]. Overexpression of miR-155
decreased the adhesion of Jurkat T cells to angiotensin II
(Ang II)-stimulated ECs. Endothelin-1 (ET-1) is a potent
vasoconstrictive peptide and mitogen that plays multiple
roles in the progression of atherosclerosis, vascular inflam-
mation and remodeling. MiR-125a and miR-125b-5p were
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the expression of oxLDL-induced ET-1 [41]. Furthermore,
miR-132 [42] was also shown to be involved in the inflam-
matory response of ECs.Angiogenesis
Angiogenesis is characterized by the formation of new
blood vessels from the existing vascular network. Angiogen-
esis is required in various physiological and pathophysio-
logical conditions such as embryonic development, tissue
regeneration, wound healing, tumor growth and athero-
sclerosis [59]. Cell proliferation and mobility are critical
steps for angiogenesis and are strictly controlled by various
intracellular signals. MiR profiling of embryonic stem (ES)
cell-derived ECs revealed a group of endothelia-enriched
miRs, including miR-126, −146, −197 and −625. MiR-126 is
most highly enriched in ECs and has been well-
characterized as a pro-angiogenic miR. MiR-126 and miR-
126* are encoded by intron 7 of the EGF-like domain 7
(Egfl7) gene, which encodes an EC-specific secreted peptide
that has been reported to act as a chemoattractant and an
inhibitor of smooth muscle cell migration [45]. Knockdown
of miR-126 in zebrafish led to a loss of vascular integrity
and induced hemorrhage during embryonic development
[46]. Targeted deletion of miR-126 in mice led approxi-
mately 40% of the miR-126−/−mice to die embryonically or
perinatally. Analysis of embryos obtained from timed mat-
ings revealed that miR-126−/− embryos were dead or dying,
with severe systemic edema, multifocal hemorrhages and
ruptured blood vessels throughout embryogenesis [39].
Analysis of gene expression profiles in ECs isolated from
miR-126−/− and zebrafish morphants demonstrated that
miR-126 promoted angiogenesis through VEGF/FGF signal-
ing by targeting its negative regulators Sprouty-related pro-
tein-1 (Spred-1) and phosphoinositide-3 kinase regulatory
subunit 2 (PIK3R2/p85-b) via the MAPK and PI3K path-
ways, respectively. The role of hemodynamic forces during
embryonic development in the patterning and remodeling
of the embryonic circulatory system has been investigated.
Nicoli et al. [47] further demonstrated that the angiogenic
sprouting of blood vessels required the blood flow-induced
transcription factor KLF-2, which induced the expression of
miR-126 to activate VEGF signaling. This study provided
new insights into how ECs respond to flow and integrate
developmental signals with miR-126 to promote angiogen-
esis. Anand et al. [48] identified that miR-132 was highly
upregulated in human ES during vasculogenesis. Interest-
ingly, miR-132 is also highly expressed in the endothelium
of human tumors and hemangiomas, but it is undetectable
in the normal endothelium. Overexpression of miR-132
leads to pro-angiogenic signals, proliferation and Ras activ-
ity via suppression of p120RasGAP in ECs. Furthermore,
selective delivery of anti–miR-132 through αvβ3 integrin-targeted nanoparticles to the tumor endothelium of mice
reduced the tumor burden and angiogenesis.
Dicer is an important RNase III enzyme for miR matur-
ation. Suarez et al. [60] clarified that the knockdown of
Dicer in ECs altered the expression of angiogenic regulators
such as Tie-2, endothelial nitric oxide synthase (eNOS) and
IL-8. Knockdown of Dicer in ECs results in a reduction of
proliferation via cell cycle delay from the G1 into the S
phase, along with impairment of cord formation. The miR-
17~92 cluster (encoding miR-17, -18a, -19a/b-1, -20a, and
-92a) is overexpressed in several tumor cells and in the
regulation of angiogenesis. Bonauer et al. [43] demonstrated
that miR-92a was highly expressed in ECs and exhibited
anti-angiogenic activity by targeting several endothelial
functional genes, including integrin subunit α5 and αv,
sphingosine-1-phosphate receptor-1 (SIP-1), and mitogen-
activated protein kinase (MAPK) kinase-4 (MKK-4). These
endothelial functional genes mediate the cell-matrix inter-
action, cell migration and angiogenesis. Furthermore, the
mouse hind limb ischemia model and myocardial infarction
model demonstrated that antagomir-92a led to enhanced
growth of blood vessels and functional recovery of damaged
tissue. Moreover, miR-210 [49], miR-221 [50], miR-222
[51], miR-100 [44], miR-424 [52] and miR-503 [53] have
also been shown to play critical roles in the modulation of
angiogenesis (Table 1).
Migration
Endothelial migration is an important property of angiogen-
esis. This motile ability is regulated by growth factors,
chemotactic factors and mechanical forces. These factors
trigger several signaling networks that converge on cytoskel-
eton remodeling in migrating cells. In recent studies, several
miRs were reported to be involved in the regulation of mi-
gration through impaired cytoskeleton remodeling related
to transcription factors and signaling molecules (Table 1).
An interesting article reported by Zhang et al. [55] demon-
strated that secreted monocytic miR-150, which is packaged
by the microvesicles (MVs), could enter and be delivered
into human microvascular ECs (HMECs), thus enhancing
cell migration and decreasing c-myc expression. These stud-
ies further revealed that blood cells and cultured THP-1
cells are able to selectively package other immune-related
miRs such as miR-146a and miR-181a into MVs in re-
sponse to various stimuli. In addition, miR-200a has been
shown to promote EC migration via the repression of
thrombrospodin-1 (THBS-1) [56]. The important miR-155
has multiple functions in ECs, not only in the regulation of
inflammation, but also in the inhibition of EC migration in
response to Ang II [40]. Ets-1 is an important endothe-
lial transcription factor that robustly regulates endothe-
lial inflammation, angiogenesis and vascular remodeling.
Bioinformatic and luciferase assays demonstrate that Ets-1
can be directly targeted by miR-155 in two potential target
Table 2 Selected miRs involved in the regulation of
macrophage/monocyte function
miRs Function Targets Reference
miR-17-5p-200-106a Monocytopoiesis AML1 [62]
miR-33 Sterol transport ABCA-1 [69,70]
miR-125a-5p Lipid uptake ORP9 [68]
miR-155 Differentiation TAB2, MyD88 [65-67]
Inflammation
Uptake of oxLDL
miR-424 Differentiation NFl-A [63,64]
Table 3 Selected miRs involved in the regulation of VSMC
function
Function miRs Targets Reference
Increase proliferation miR-21 PTEN, Bcl-2 [71]
miR-130a GAX [75]
miR-146a KLF-4 [74]
miR-221/222 p27, p57 [72,73,76]
Decrease proliferation miR-26 SMAD [77]
miR-133 Sp-1 [78]
miR-143/145 KLF-5 [79,80]
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angiogenesis and contributes to the development of the vas-
cular network. Small et al. [57] demonstrated that miR-218
was expressed from the slit2 and slit3 genes, resulting in fur-
ther direct repression of the expression of Robo1, Robo2,
and glucuronyl C5-epimerase (GLCE), resulting in a reduc-
tion of EC migration. This intact miR-218-Slit-Robo regula-
tory network is necessary for the vascularization of the
retina. MiRs have been reported to decrease EC migration,
including miR-21 [54] and miR-320 [58] via repression of
RhoB and insulin-like growth factor-1 (IGF-1), respectively.
Macrophages/monocytes
Monocytic differentiation and oxLDL uptake are critical pro-
cesses in atherosclerosis. Wang et al. [61] integrated micro-
array data and a bioinformatic database to reveal the
correlations between miR and target mRNA in the TPA-
induced differentiation of U937 cells. Fontana et al. [62]
demonstrated the role of miR-17-5p-20a-106a in one mono-
cyte lineage from the cord blood CD34+ hematopoietic
progenitor cells (HPCs). MiR-17-5p–20a–106a suppresses
AML1 protein expression, leading to the downregulation of
the M-CSF receptor (M-CSFR) and the inhibition of monocy-
topoiesis. In contrast, using the same model cell type, Rosa et
al. [63] revealed that miR-424 promoted monocytic differenti-
ation through the repression of NFI-A, the transcription fac-
tor used to regulate monocytic differentiation. An Agilent
miR array revealed that miR-155, −222, -424, and −503 are
involved in monocytic differentiation through cell cycle arrest
and apoptosis [64]. In addition to these miRs, miR-155 is also
implicated in the regulation of monocyte-derived dendritic
cells [65], macrophage inflammatory responses [66] and up-
take of oxLDL. Huang et al. [67] demonstrated the miR-155
could reduce the lipid uptake in oxLDL-stimulated and
PMA-differentiated THP-1 cells. MiR-125a-5p was shown to
decrease lipid uptake and the secretion of inflammatory cyto-
kines, including IL-2, IL-6, TNF-α and TGF-β, in oxLDL-
stimulated human primary monocytes via the repression of
oxysteral binding protein like-9 (ORP9) [68]. MiR-33 has
been reported to play a role in sterol transport [69,70]. MiR-
33 is an intronic miR that localizes within the gene encoding
sterol-regulatory element–binding factor–2 (SREBF-2) and
acts as a transcriptional regulator of cholesterol synthesis to
modulate the expression of genes related to cholesterol trans-
port. MiR target prediction algorithms and overexpression of
miR-33 in mouse macrophages identified the adenosine tri-
phosphate–binding cassette transporter (ABCA-1) as a miR-
33 target gene. Antagonism of endogenous miR-33 increased
ABCA1 protein and cholesterol efflux to apolipoprotein A1
in both murine and human macrophages (Table 2).
Smooth muscle cells
Neointima formation is commonly attributed to VSMC pro-
liferation. Several reports have demonstrated the involvementof miRs in the mediation of VSMC proliferation and migra-
tion (Table 3). In rat balloon-injured carotid arteries and
cultured rat VSMCs, miR-21 [71], miR-221 [72] and miR-
222 were shown to play roles in the regulation of VSMC
proliferation through phosphatase and tensin homology
(PTEN), B-cell lymphoma 2 (Bcl-2) and p27(Kip1), p57
(Kip2), respectively. PTEN and Bcl-2 have been reported to
serve as important molecules associated with VSMC prolif-
eration and apoptosis. p27(kip1) and p57(kip2) are critical
molecules involved in cell cycle regulation and were demon-
strated to be negative regulators in VSMC proliferation [73].
In general, miR-146a is known to serve an anti-
inflammatory function in various cells (as mentioned
above). Sun et al. [74] further substantiated that miR-146a
directly targets Krupple-like factor-4 (KLF-4) and demon-
strated its important role in promoting VSMC proliferation
in cultured rat VSMCs and vascular neointimal hyperplasia.
Interestingly, miR-146a and KLF-4 formed a feedback loop
regulating each other’s expression. KLF-4 inhibited miR-
146a at the transcriptional level, while miR-146a inhibited
the expression of KLF-4 by targeting the 3’-UTR region of
KLF-4. Another member of the KLF family, KLF-5, pro-
moted the transcription of miR-146a and acted as a com-
petitor with KLF-4. These molecules form a regulatory
circuitry to precisely modulate the proliferation of VSMCs.
Wu et al. [75] found that miR-130a correlated with vascular
remodeling in spontaneously hypertensive rats (SHRs).
MiR-130a was up-regulated in the thoracic aorta and
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sion and protein level of growth arrest-specific homeobox
(GAX) were downregulated by miR-130a. MiR-130a mimics
at 25 or 50 nmol/l significantly promoted the proliferation
of VSMCs.
Some miRs were found to take part in the repression of
VSMC proliferation. The miR-143/145 cluster is abun-
dantly expressed in the normal vessel walls. Interestingly,
miR-143/145 is dramatically downregulated in injured ca-
rotid arteries after angioplasty [79,80]. MiR-143 is highly
conserved and lies within 1.7 kilobases (kb) of another
miR145 on the mouse chromosome 18. Both miRs are
downregulated in various cancer cell lines [81]. Cheng et al.
[80] further demonstrated that miR-145 is a critical modu-
lator for VSMC differentiation through its target gene KLF-
5. The expression of VSMC differentiation marker genes
such as SM α-actin, calponin and SM-MHC were increased
at the gene and protein levels using a miR-145 mimic oligo-
nucleotide. In contrast, overexpression of KLF-5 reduced
the gene expression of SM α-actin. These results provide
evidence of a correlation between miR-145 and KLF-5 in
VSMC differentiation. MiR-26a was selected from growth-
arrested human aortic SMCs by an miR array [77]. This
profile revealed that miR-26a was significantly upregulated
in differentiated VSMCs through a decrease of SMAD ac-
tivity. In addition, miR-26a was dramatically downregulated
in two murine AAA development models, abdominal aortic
aneurysms (AAAs) and ApoE−/−/AngII aneurysm. MiR-133
is robustly expressed in VSMCs in vitro and in vivo [78]. In
serum-starved synchronized adult rat carotid VSMCs, miR-
133 was abundant and indirectly regulated VSMC marker
genes and proteins through the Sp-1 transcription factor.
Roles of microRNA in atherosclerosis
Blood vessels are constantly subjected to various hemodynamic
forces, including hydrostatic pressure, cyclic stretch and
fluid shear stress. As the monolayer is in direct contact with
flowing blood, vascular ECs are constantly exposed to blood
flow-induced shear stress. Extensive evidence has shown
that hemodynamic forces may play prominent roles in the
development of vessel maturation, physiology and patho-
physiology. Atherosclerosis occurs preferentially in arterial
branches and curvatures where the shear stress is low and
dynamic [2], and the initial step is attributed to EC dysfunc-
tion. Oscillatory shear stress (OSS) induces the expression
of miR-21 at the transcriptional level in cultured ECs and
eventually leads to an inflammatory response through per-
oxisome proliferators-activated receptor-α by 3'-UTR tar-
geting [82]. Wu et al. [83] demonstrated that pulsatile
shear stress (PSS) downregulated but OSS upregulated the
expression of miR-92a in ECs. Previous studies have shown
that KLF-2 was significantly upregulated by atheroprotec-
tive shear flow such as PSS and laminar shear stress. Bioin-
fomatic analysis demonstrated that KLF-2 serves as a targetgene for miR-92a, and its gene and protein levels were
downregulated by OSS-stimulated ECs. In addition, the
KLF-2 regulated-genes such as eNOS and thrombomodulin
(TM) were repressed by overexpression of miR-92a in ECs.
This study provides a new concept for the regulatory cir-
cuitry of the responses of KLF-2 and miRs to atheroprotec-
tive shear flow. MiR-663 [84], miR-19a and miR-23b
[85,86] have also been studied and shown to be regulated
by shear stress and involved in the modulation of EC in-
flammation and proliferation, respectively.
The functions of various miRs and their involvement in
biological processes have been identified in various cultured
cells or animal models. The expression profiles of circulating
miRs [87] and peripheral blood mononuclear cells (PBMCs)
[88-91] in patients with cardiovascular diseases have been
extensively studied. Unfortunately, the involvement of miRs
in human atherosclerotic plaques has received little atten-
tion. Raitoharju et al. [92] were the first to investigate the
miR/mRNA expression profiles in human atherosclerotic
plaques from peripheral arteries (carotid, femoral, and the
aorta) in comparison to non-atherosclerotic left internal
thoracic arteries (LITA), and they elucidated the relationship
between miR/mRNA expression profiles and biological
processes in atherosclerosis. They found that miR-21, -34a,
-146a, -146b-5p, and −210 were expressed at significant
levels, and numerous predicted targets of these miRs were
downregulated in human atherosclerotic plaques. The
combination of miR/mRNA profiles and bioinformatic
analysis showed that nine KEGG pathways were enriched
with predicted targets, including immunodeficiency, me-
tabolism, p53 and cell proliferation signaling pathways.
Interestingly, among these pathways, cancer-related path-
ways are significantly upregulated. In contrast, VSMC con-
traction and purine metabolism were downregulated in
human atherosclerotic plaques compared to LITAs. MiR-
34a was identified as a new target for atherosclerotic
pathogenesis due to its function in apoptosis and cell cycle
arrest, its modulation of the p53 signaling pathway, and its
target genes related to VSMC proliferation and cholesterol
metabolism. Taken together, these links strongly support
the connection of miR-34a to cardiovascular diseases.
MiR-146a is highly expressed in both human atheroscler-
otic plaques and PBMCs [88,89] in patients with cardiovas-
cular diseases It was previously shown that the miR-146
family (miR-146a/b) regulated downstream toll-like recep-
tor 4 (TLR4) signaling, IL-1 receptor associated kinase-1
(IRAK1) and TNF-receptor associated factor-6 (TRAF6)
through a negative-feedback regulation loop. IRAK and
TRAF6 activated the downstream transcription factors NF-
κB and AP-1 and then upregulated the TLR4-mediated im-
mune response. Elevated miR-146 expression was shown
to act in an NF-κB-dependent manner by utilizing an LPS
(lipopolysaccharide)-stimulated human monocytic cell line
[93].
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ferred through the gap junction or secreted between cells
[94-96]. Surprisingly, miRs are present in serum or plasma
in a remarkably stable form that even resists repetitive
freezing/thawing cycles and are protected against RNases.
Fichtlscherer et al. [87] performed a miR profile using RNA
isolated from 8 healthy volunteers and 8 patients with stable
coronary artery disease. The circulating levels of angiogenesis-
related miR-126 and miR-92a, the inflammation-associated
miR-155, VSMC–enriched miR-145 and miR-17 are signifi-
cantly reduced in patients with coronary artery disease com-
pared with healthy controls. In contrast, cardiac muscle–
enriched miRs, miR-133a and miR-208a levels were shown to
be elevated in patients with coronary artery disease. The exact
mechanisms of reduction of circulating miRs remain unclear.
Supposedly, the activity of ECs may contribute to the lower
levels of circulating miRs. Another implication may be that
circulating miRs are taken up into atherosclerotic lesions,
leading to a reduction of circulating miRs in blood. Overall,
this article raises the potential role of circulating miRs as bio-
markers for diagnosis of cardiovascular diseases.
Roles of microRNA in restenosis
Rat carotid artery balloon injury is a common animal
model to study restenosis [36]. Ji et al. [71] were the first
to determine the miR profile in the rat carotid artery after
balloon injury utilizing an miR array. Aberrant overexpres-
sion of miR-21 was determined at a significant level in
neointimal lesions. The miR-21 gene is located on the plus
strand of chromosome 17q23.2 within the coding gene
TMEM49 (also known as vacuole membrane protein).
This gene was first described as an oncomir due to its
abundant expression in various cancers [97]. MiR-21 is
involved in the promotion of VSMC proliferation and
anti-apoptosis by directly targeting PTEN and PDCD4
[98], respectively. In addition, Liu et al. [72] and Davis et
al. [76] clarified the role of miR-221 and miR-222 in
VSMC proliferation and neointimal hyperplasia. MiR-221
and miR-222 are encoded by a gene cluster on the X
chromosome, they share the same seed and appear to have
identical target genes and similar functions. Both miRs are
significantly mediated by PDGF-BB and serum treatment
in cultured VSMCs. Liu et al. [72] further demonstrated
that expression of miR-221 and miR-222 were upregulated
in balloon-injured rat carotid arteries and their target
genes, p27(Kip1) and p57(Kip2), were downregulated.
Downregulation of miR-221 and miR-222 reduced the
proliferation of VSMCs and neointima formation in the
rat carotid artery after angioplasty.
Recently, several studies demonstrated the role of the
miR-143/miR-145 cluster in VSMC differentiation and vas-
cular disease [79,80,99-101]. Cordes et al. [79] first revealed
the distribution of miR-143/miR-145 during embryonic de-
velopment. Postnatally, the transcript levels of the miR-143/miR-145 cluster are high in smooth muscle of the aorta,
pulmonary artery and coronary vessels but undetectable in
the ventricular myocardium. Furthermore, miR-143 and
miR-145 cooperatively target a network of transcriptional
factors including Elk-1 (ELK1 is a member of the ETS
oncogene family), KLF-4 and myocardin to promote differ-
entiation and repress the proliferation of VSMCs. MiR-143/
miR-145 knockout (KO) mice were also established in ad-
vance to clarify the maintenance of the contractile pheno-
type of VSMCs [99-101]. Elia et al. [100] showed that the
aorta of apolipoprotein E (ApoE) KO mice, in which vascu-
lar damage is enhanced by a hypercholesterol diet, exhibits
markedly decreased constitutive levels of miR-143 and
miR-145. Albinsson et al. [102] generated Dicer KO mice
and found late embryonic lethality at embryonic day 16 to
17 associated with extensive internal hemorrhage. Expression
of miRs, including miR−21, −221, -145 and VSMC-specific
marker genes are significantly reduced in SMC-Dicer KO
vessels. Interestingly, overexpression of miR-145 rescued
SMC-specific mRNA and protein expression in dicer KO
SMC by miR-145 mimics. This finding indicates that an add-
itional miR-dependent mechanism is necessary during
VSMC development rather than Dicer because the loss of
Dicer in mice is lethal. These studies demonstrated the im-
portant role of miR-145 in VSMC differentiation and vascu-
lar disease.
Summary and conclusion
Atherosclerosis is a widespread condition with high morbidity
and mortality in both developed and developing countries. Its
complications, including unstable coronary syndromes, myo-
cardial infarction and stroke, usually cause high mortality in
patients. Several medications and surgical procedures have
been used for clinical therapy. Patients with atheroscler-
otic disease are usually treated by angioplasty with stent
replacement. However, restenosis is commonly observed
in angioplasty patients. Both pathologies are underlined by
complicated pathophysiological processes, and extensive
studies on cellular mechanisms have been well established
to seek opportunities for clinical therapy. MiRs are a novel
class of gene regulators, and their important roles and
functions in vascular biology have been demonstrated in
over 400 reports. This review summarizes the current
understanding of the roles of miRs in atherosclerosis and
restenosis. ECs, VSMCs and blood cells contribute to both
vascular pathologies. Each cell type has a specific role in
these two conditions, with ECs exhibiting an inflammatory
response, angiogenesis and migration; VSMCs undergoing
differentiation and proliferation; and blood cells modulat-
ing oxLDL uptake and lipid metabolism. Hence, we focus
on the different features of each type of cell to elucidate
how miRs modulate these cellular functions. We discussed
the significant changes in miR expression profiles that
occur in human specimens with atherosclerosis and
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insight into the potential clinical applications of miRs and
emphasize the importance of miRs in the pathogenic pro-
cesses of vascular diseases. Interestingly, some miRs are
altered in vitro and in vivo studies, for example, miR−126,
−17~92a, −145, −21 and −146a. Some miRs can only be
expressed in specific tissues or cells with a special status.
The EC-specific miR-126 and VSMC-specific miR-145 are
usually enriched in blood vessels during embryonic devel-
opment and in mature vessels. Supposedly, these miRs are
involved in the maintenance of homeostasis or develop-
ment of blood vessels. MiR-21 and miR-221/222 have
been investigated as promoters of the proliferation of
VSMCs via negative modulation of cell cycle regulation as
well as of PTEN and p27. MiR-21 is also referred to as an
oncomir due to its high expression levels in various cancer
cell lines. This implies that these miRs contribute to vas-
cular pathogenesis. Some miRs are expressed in multiple
cells, such as miR-146a and miR-155, which are expressed
in both ECs and blood cells to induce a cellular inflamma-
tory response and protect blood vessels, respectively. This
indicates that miRs may have great potential as therapeu-
tics. Interestingly, recent advances have enabled the identi-
fication of miRs released into circulating blood from
injured tissue or highly expressed in patients with cardio-
vascular diseases. This implies that circulating miRs and
tissue/cell-specific miRs are potential biomarkers for clin-
ical diagnosis in patients with cardiovascular diseases. The
overall body of evidence shows that miRs have emerged as
a new layer of complexity in vascular diseases and may
represent novel biomarkers and new therapeutic targets
for cardiovascular diseases.
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